Intellia Therapeutics, Inc

NTLANASDAQ • USD
9.70 USD
↘ 0.85 (8.06%)AT CLOSE (03:59 PM EST)
9.81
↗ 0.11 (1.14%)
POST MARKET (AS OF 07:58 PM EST)
Post Market
AS OF 07:58 PM EST
9.81
↗ 0.11 (1.14%)
🔴Market: CLOSED

NTLA is currently priced at $9.71. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. NTLA is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$10.45
High?$10.51
Low?$9.67
Prev. Close?$10.55
Volume?11.4M
Avg. Volume?5.3M
VWAP?$10.02
Rel. Volume?2.16x
Bid / Ask
Bid?$9.77 × 1.3K
Ask?$9.85 × 900
Spread?$0.08
Midpoint?$9.81
Valuation & Ratios
Market Cap?1.4B
Shares Out?140.4M
Float?115.1M
Float %?82.1%
P/E Ratio?N/A
P/B Ratio?2.22
EPS?-$3.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees
377
Market Cap
1.4B
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed
2016-05-06
Address
400 TECHNOLOGY SQUARE
CAMBRIDGE, MA
Phone: 857-285-6200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
27
Short Sent.?
30
Piotroski F-Score?1/9Weak
Altman Z-Score?-2.67Distress
Confidence?70%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?38.56%Squeeze Risk
Short Interest?44.4M
Days to Cover?11.1
Free Float115.1M
Avg Daily Volume4.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?6.31Strong
Quick Ratio?6.31Strong
Cash Ratio?1.94Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
69
2.22CHEAP▾
P/S?
Peers
50
S&P
3
25.74HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.0CHEAP▾
EV/Sales?
Peers
50
S&P
3
24.19HIGH▾
Returns & Efficiency
ROE?
S&P
3
-69.5%WEAK▾
ROA?
S&P
3
-47.2%WEAK▾
Cash Flow & Enterprise
FCF?$-358076000
Enterprise Value?$1.3B
Fundamentals ratios updated end of day